Regulation of immune functions by combined Jinlong capsule and interventional therapy in patients with primary liver cancer
-
摘要:
目的 观察金龙胶囊联合介入治疗对原发性肝癌患者免疫功能的调节作用。 方法 随机选择经临床确诊为中晚期原发性肝癌的住院患者60例，随机分为观察组和对照组，观察组患者在介入治疗后第3天开始口服金龙胶囊，3次/日，4粒/次，30 d为1个疗程。对照组患者仅进行介入治疗。治疗过程中两组均不使用其他免疫调节剂。两组患者均于介入治疗前3~5 d及介入治疗后1个月采集外周血标本检测细胞免疫功能指标。 结果 观察组患者介入治疗后外周血CD3、CD4、NK细胞、CD4/CD8比值、SIL-2R和TSGF数量（均值）与治疗前均无显著变化。对照组患者介入治疗后外周血CD3、CD4、NK细胞、CD4/CD8比值、SIL-2R和TSGF数量（均值）较治疗前均显著降低（P< 0.05）。 结论 金龙胶囊有助于原发性肝癌患者介入治疗后细胞免疫功能的恢复。 Abstract:Objective To determine the effects of Jinlong capsule combined with interventional therapy on the immune functions of primary hepatocellular carcinoma patients. Methods Sixty randomly selected cases of clinically diagnosed primary hepatocellular carcinoma were divided into the observation group and the control group. Three days after operation, the observation group was given four Jinlong capsules three times a day for 30 days (one treatment). Meanwhile, the control group received interventional therapy after the operation. One to four days following one treatment, peripheral blood specimens were collected from the two groups to determine the cellular immune function indices. Results The cell numbers (mean) of the peripheral blood components CD3, CD4, NK, SIL-2R, TSGF, and SIL-2R and the CD4/CD8 ratio in the observation group showed no significant difference before and after treatment. In the control group, these indices were significantly different before and after treatment. Conclusion The Jinlong capsule facilitates the cellular immunity recovery of patients with primary hepatocellular carcinoma after interventional therapy. -
Key words:
- Jinlong capsule /
- combination /
- interventional therapy /
- primary liver cancer /
- immunity
-
表 1 两组患者治疗前后T淋巴细胞亚群和NK细胞数量的变化 （x±s）
Table 1. Comparison of the T lymphocyte subsets and NK cell volumes of patients between the two groups before and after treatment (x±s)
表 2 两组患者治疗前后肿瘤免疫相关因子的变化 （x±s）
Table 2. Comparison of the tumor immune relevance factor of patients between the two groups before and after treatment (x±s)
-
[1] 陈建国, 宋新明. 中国肝癌发病水平的估算及分析[J]. 中国肿瘤, 2005, 14(1): 28-30. https://www.cnki.com.cn/Article/CJFDTOTAL-ZHLU200501008.htm [2] 刘玉琴, 高进, 顾蓓, 等. 金龙胶囊(JLC)对肿瘤细胞诱导分化作用的研究[J]. 中国肿瘤临床, 2004, 31(20): 380-383. [3] 赵剑波, 李彦豪, 陈勇, 等. 原发性肝癌患者介入治疗后生命质量得分的变化分析[J]临床放射学杂志, 2002, 21(7): 550-552. doi: 10.3969/j.issn.1001-9324.2002.07.018 [4] 高益民. 蛋白质组学与中药鲜动物药研究－金龙胶囊上市10年后评价[J]. 中国肿瘤临床, 2008, 35(7): 415-418. [5] 苗明三. 对细胞凋亡研究的认识[J]. 河南中医学院学报, 2003, 18(3): 27-31. doi: 10.3969/j.issn.1003-5028.2003.03.022 [6] 贾立群, 李学, 万冬桂, 等. 金龙胶囊的免疫双向调节作用[J]. 北京医学, 2005, 27(9): 550-552. doi: 10.3969/j.issn.0253-9713.2005.09.013 [7] 徐淑玲, 王笑红, 张永祥, 等. 金龙胶囊对免疫受抑小鼠淋巴细胞亚群的影响[J]. 中国中医基础医学杂志, 2005, 11(12): 908-909. doi: 10.3969/j.issn.1006-3250.2005.12.013 [8] 孙保木, 罗明, 吴胜兵, 等. 金龙胶囊联合肝动脉栓塞化疗治疗胃癌伴肝转移[J]. 中西医结合学报, 2008, 6(9): 968-970. https://www.cnki.com.cn/Article/CJFDTOTAL-XBZX200809024.htm [9] 刘玉琴, 高进, 李建生. 金龙胶囊抗肿瘤复发、转移的实验研究[J]. 北京医学, 2005, 27(9): 554-557. doi: 10.3969/j.issn.0253-9713.2005.09.015 [10] 李玉衡. 多成分现代鲜药对肿瘤的影响-金龙胶囊能明显抑制肿瘤生长、复发、转移[J]. 首都医药, 2006, 13(2): 39-40. doi: 10.3969/j.issn.1005-8257.2006.02.020 [11] 郝仙娣, 主编. 现代鲜药金龙胶囊研究与作用机制探讨[M]. 中国肿瘤临床年鉴. 北京: 中国铁道出版社, 2005: 301-306. [12] 刘玉琴, 高进, 薛克勋, 等. 金龙胶囊(JLC)对小鼠U14瘤株的抑制生长和自发转移实验研究[J]. 中国新药杂志, 2001, 10(11): 823-825. doi: 10.3321/j.issn:1003-3734.2001.11.008 [13] 徐淑玲, 王笑红, 张永祥. 金龙胶囊对免疫受抑小鼠淋巴细胞亚群的影响[J]. 中国中医基础医学杂志, 2005, 11(12): 908-909. doi: 10.3969/j.issn.1006-3250.2005.12.013 [14] 石怀芝. 金龙胶囊配合辨证施治治疗原发性肝癌30例临床观察[J]. 北京中医, 2000, 19(5): 30-32. https://www.cnki.com.cn/Article/CJFDTOTAL-BJZO200005012.htm [15] 杨光伟, 高时英, 覃强. 金龙胶囊合并放疗治疗鼻咽癌临床观察[J]. 中国肿瘤临床, 2002, 29(7): 529-532. [16] 杨晓丽. 金龙胶囊对小细胞肺癌患者血清NSE水平的影响[J]. 中华医学杂志, 2007, 87(17): 1210-1211. [17] 孙建海, 杨水生, 马燕凌. 金龙胶囊对晚期肝癌生存质量及生存期的影响[J]. 湖北中医杂志, 2006, 28(5): 34. https://www.cnki.com.cn/Article/CJFDTOTAL-HBZZ200605017.htm [18] 郝仙娣, 周哲, 李树新. 金龙胶囊抑瘤及配合化疗减毒作用的观察[J]. 中国肿瘤临床与康复, 1998, 5(增刊): 40-42. -
点击查看大图
表(2)
计量
- 文章访问数: 16
- HTML全文浏览量: 10
- PDF下载量: 0
- 被引次数: 0
下载:
